Is There any Loophole in the Roadmap Model?

帅庭

文章导读：于核苷（酸）类似物治疗慢性乙型肝炎的路线图概念（roadmap concept），Edward J. Gane教授认为存在以下几点漏洞

High levels of HBV replication are associated with increased risk of cirrhosis, decompensation, hepatocellular carcinoma and liver related mortality. In addition, long-term studies of antiviral therapy for CHB have demonstrated that sustained suppression will prevent disease progression and complications. Today, Professor Edward J. Gane who came from New Zealand Liver Transplant Unit, New Zealand, presented a report on the “Roadmap Concept”.  He said that profound and sustained inhibition of viral replication is the most important goal of antiviral therapy in chronic hepatitis B. Multiple analyses of baseline factors and on-treatment responses have identified that the absolute HBV DNA level after 24 weeks of therapy as the best predictor of long-term efficacy. This on-treatment management algorithm where virologic responses at 24 weeks are used to identify those patients with suboptimal responses so that an appropriate change in therapy can be initiated in order to enhance long-term patient outcomes is called the “Roadmap Concept”.

However，Professor Edward J. Gane thought there are several potential loopholes in the practical application of this approach:

更多精彩内容请点击：http://apasl2009-cn.ihepa.com/17-170-2058.html